Iżrael - Ingliż - Ministry of Health

mbi pharma ltd., israel - dexamethasone phosphate ( as sodium phosphate ) - solution for injection / infusion - dexamethasone phosphate ( as sodium phosphate ) 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Kenja - Ingliż - Pharmacy and Poisons Board

dawa limited p.o box 16633-00620 nairo, kenya - dexamethasone sodium phosphate - injection - dexamethasone sodium phosphate equiv. to… - plain corticosteroids for systemic use:

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - dexamethasone phenylpropionate; dexamethasone sodium phosphate - parenteral liquid/solution/suspension - dexamethasone phenylpropionate steroid-glucocorticoid active 2.0 mg/ml; dexamethasone sodium phosphate steroid-glucocorticoid active 1.0 mg/ml - endocrine system - cat | cattle | dog | goat | horse | pigs | sheep | beef | billy | bitch | boar | bos indicus | bos taurus | bovine | buck | buff - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

max health limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: disodium edetate nitrogen propylene glycol sodium hydroxide water for injection - dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid. when so supplemented, dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; · relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; · primary and secondary adrenocortical insufficiency.

Malta - Ingliż - Medicines Authority

rosemont pharmaceuticals limited rosemont house, yorkdale industrial park, braithwaite street, leeds ls11 9xe, united kingdom - dexamethasone - oral solution - dexamethasone 10 mg/5ml - corticosteroids for systemic use

Malta - Ingliż - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - dexamethasone - oral solution - dexamethasone 2 mg - corticosteroids for systemic use

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - dexamethasone sodium phosphate - solution for injection - 4 milligram(s)/millilitre - dexamethasone

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - dexamethasone - tablet - dexamethasone

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - dexamethasone - tablet - dexamethasone

Kenja - Ingliż - Pharmacy and Poisons Board

dexamethasone sod.phosphate 4mg/1ml inj 10's - injection - dexamethasone sod.phosphate 4mg/1ml inj 10's 4mg - dexamethasone